Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12274267 | 0.84 | CA2 (0.38) | CA2CA12CA14DGAT1CTSK | |
| SCHEMBL783009 | 0.81 | CA2 (0.41) | CA2CA12CA14DGAT1CTSK | |
| SCHEMBL308857 | 0.79 | EPHX2 (0.39) | CA2CA12CA14DGAT1CTSK | |
| Hydrochloric Acid SCHEMBL6245737 | 0.79 | CA2 (0.35) | CA2CA12CA14DGAT1CTSK | |
| SCHEMBL27589470 | 0.79 | CTSK (0.37) | CA2CA12CA14DGAT1CTSK | |
| SCHEMBL1841358 | 0.78 | LATS1 (0.37) | CA2CA12CA14DGAT1CTSK | |
| SCHEMBL6535041 | 0.77 | MAOA (0.44) | CA2CA12CA14DGAT1CTSK | |
| SCHEMBL125503 | 0.77 | TDP1 (0.52) | CA2CA12CA14MAOAMAOB | |
| SCHEMBL3253463 | 0.77 | CA12 (0.36) | CA2CA12CA14DGAT1CTSK | |
| SCHEMBL2141079 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331503-B1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2013-08-21 | — | — | EP | claimed |
| US-8334288-B2 | 4-phenoxymethylpiperidines as modulators of GPR119 activity | IRM LLC (BM) | 2012-12-18 | — | — | US | claimed |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | claimed |
| EP-2134704-B1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-09-22 | — | — | EP | claimed |
| US-5304645-A | Colored or fluorescent labels | BOEHRINGER MANNHEIM GMBH (DE) | 1994-04-19 | — | — | US | claimed |
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | claimed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
| CN-86106023-A | Be used for solid-phase peptide synthetic novel vector | — | 1987-02-25 | — | — | CN | claimed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2022265577-A2 | CORONAVIRUS ENZYME MODULATORS, METHODS OF SYNTHESIS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-22 | — | — | WO | disclosed |
| EP-4000640-A1 | DUAL MODE RADIOTRACER AND THERAPEUTIC | Technische Universität München (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3129014-B1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | TETRAHEDRON (FR) | 2021-05-12 | — | — | EP | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
| WO-2019020831-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2019-01-31 | — | — | WO | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0228192-A2 | Renin-inhibitory oligopeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0209875-A1 | Resorufin derivatives and process for their preparation | Roche Diagnostics GmbH (DE) | 1987-01-28 | — | — | EP | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | CA2 2618/4885CA12 2905/4885CA14 3507/4885 |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR4, GPR180 | CA2 1639/4885CA12 4637/4885CA14 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.